Azitra's platform uses a strain of the skin microbiome, S. epidermidis, to modify the skin microbiome and deliver therapeutic protein to the target. The platform is modular and can modify S. epidermidis to secrete an array of therapeutically relevant proteins necessary in the treatment of multiple skin diseases.
Azitra's work is supported by NIH grants, private grants, and investment from and .
In May 2018, Azitra announced that it had secured $2.15 million in convertible debt financing to support advancement of the company's pipeline of dermatology and skin care products. The financing was led by new investor , and existing investor Bios Partners. An additional new investor, , joined the syndicate. This financing brings the total raised to date to $5.4 million.
Funding was led by Bios Partners and Connecticut Innovations
President and CEO
Founder and CSO
The Microbiome Movement: Commensal Cosmetics Offer a Viable Future
Travis Whitfill, Azitra Inc., Farmington, CT and Yale University School of Medicine, New Haven, CT USA